Morgen is a time management platform that simplifies the scheduling process by integrating multiple calendars and task management tools into a single application. As the complexity of time management increases, Morgen addresses this challenge by offering a holistic solution that allows users to plan, organize, and optimize their schedules effectively. The platform combines various calendar systems and communication channels, enabling users to manage all events, tasks, lists, and reminders in one place. With its native scheduling tool, Morgen helps individuals and teams reduce meeting chaos and streamline their daily activities, making time management more efficient and less fragmented.
Ninox Software GmbH, based in Berlin, Germany, develops business applications that empower teams to automate back-office workflows without requiring developer assistance. Utilizing a no-code approach, Ninox enables over 2,800 companies across various industries to digitize their business processes efficiently. The company distinguishes itself in the rapidly growing no- and low-code application platform market by offering a user-friendly experience that combines the ease of modern productivity tools with the flexibility of application platforms. This facilitates broader adoption among organizations, as Ninox streamlines the onboarding process while reducing the time and effort needed to create custom business applications.
Picterra SA operates an online platform that automates artificial intelligence (AI) workflows for object detection to extract geo-information. Founded in 2016 and headquartered in Écublens, Switzerland, the company integrates AI with satellite, drone, and aerial data to help users monitor and anticipate environmental changes. Picterra serves various sectors, including aerial imaging and mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, as well as public organizations and NGOs. The platform is designed to empower users by allowing them to train and customize AI models without requiring programming or deep learning expertise, thus facilitating the extraction of relevant geo-information tailored to their specific needs.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.
turicode Inc. develops software as a service (SaaS) platform for document processing. Its software reads and understands documents such as PDFs, scans, and emails. The company’s MINT.extract platform helps companies and their employees to digitize document. It serves legal and tax, financial industry, healthcare, logistics, insurance, and archives industries. turicode Inc. was founded in 2016 and is based in Winterthur, Switzerland.
Ledgy AG, a technology company, operates Software-as-a-Service platform to manage and exchange securities in private companies. Its platform is used for shares management for companies and shareholders. The company was founded in 2017 and is based in Zurich, Switzerland.
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease. CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensive insulin therapy but want flexibility and freedom from multiple daily injections. CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
SMART VALOR AG is a blockchain-based startup located in Zug, Switzerland, that focuses on creating a decentralized marketplace for tokenized alternative investments. Founded in 2017, the company leverages the Swiss legal framework to combine the security and privacy of a leading banking center with the accessibility of blockchain technology. SMART VALOR enables direct connections between banks and a decentralized network of investors, facilitating a range of investment solutions in areas such as real estate, currencies, venture capital, and art. Additionally, the company offers services related to know your customer (KYC) compliance and performance tracking within its ecosystem, thereby promoting borderless crypto finance and secure custody for crypto assets.
Gamaya SA specializes in farmland analytics solutions aimed at enhancing the efficiency and sustainability of agricultural practices. Founded in 2015 and based in Lausanne, Switzerland, the company offers a range of tools tailored to specific crops, including SOYFIT for soybean cultivation, CANEFIT for sugarcane, and an Agronomic Intelligence Platform for large-scale tobacco growers. Gamaya's solutions enable early detection of diseases, pests, and weeds, as well as stress diagnostics and growth monitoring, which help optimize fertilization and predict yields. By leveraging advanced mapping and diagnostic technologies, Gamaya supports both large industrial farms and small-holder farmers in making informed decisions that improve production efficiency while minimizing environmental impact.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.
MESA Imaging is focusing on the development and production of 3D time-of-flight cameras.
Ledgy AG, a technology company, operates Software-as-a-Service platform to manage and exchange securities in private companies. Its platform is used for shares management for companies and shareholders. The company was founded in 2017 and is based in Zurich, Switzerland.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
picoDrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. Its Electrothermal Selffocussing method allows the controlled heating and evaporation of precisely defined volumes in dielectric materials. The company is based in Lausanne, Switzerland.
Lambda Health System SA specializes in the development and commercialization of innovative rehabilitation technology, particularly focusing on a robotic device known as the Lambda Robot. This device is designed to assist patients with locomotor disabilities, facilitating rehabilitation across various fields including neurorehabilitation, orthopedics, and geriatrics. The Lambda Robot allows therapists to perform exercises without the need for patient transfers between different machines, streamlining the rehabilitation process. Additionally, the company offers the Lambda Control Center, a platform that enables physicians to tailor exercises to individual patient needs while monitoring their progress and adjusting training parameters as necessary. The control center also incorporates engaging games and virtual reality applications aimed at addressing cognitive disorders. Founded in 2015 and based in Yverdon-Les-Bains, Switzerland, Lambda Health System emerged as a spin-off from the University of Applied Sciences of Canton de Vaud, focusing on creating cost-effective and user-friendly rehabilitation solutions.
Advanon AG, based in Zurich, Switzerland, operates an online financial services platform that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015, the platform allows businesses to pre-finance their invoices, enabling them to access liquidity without the long wait times typically associated with customer payments, which can range from 30 to 120 days. This service provides SMEs with flexible financing options that help strengthen their cash flow and support growth. Advanon is recognized as a financial intermediary and complies with regulatory standards set by the Swiss Financial Market Supervisory Authority (FINMA) under the Anti Money Laundering Act.
Altoida AG, founded in 2016 and based in Lucerne, Switzerland, specializes in developing a healthcare platform and application aimed at Alzheimer’s patients. The company's flagship product, the Altoida iPad-based application, is the first validated solution on the market designed to predict the risk of Alzheimer’s Disease before symptoms appear, functioning as a computational biomarker. The application employs the Neuro Motor Index (NMI), which measures subtle micro-errors and micro-movements during everyday tasks, allowing for early detection of cognitive decline up to six years prior to the onset of typical neurodegenerative symptoms. The NMI test is intended for use by healthcare professionals as an adjunctive tool and is not a stand-alone diagnostic method. Altoida's medical device is classified as an FDA Class II medical device and CE marked as Class I, enabling early screening for Mild Cognitive Impairment (MCI) and monitoring cognitive function. After a brief testing period, healthcare providers receive real-time access to comprehensive patient reports via a secure, HIPAA-compliant web dashboard, making cognitive health assessments more affordable and accessible.
Inositec AG is a biotechnology company based in Zurich, Switzerland, established in 2015 as a spin-off from ETH Zurich. The company specializes in the development of drug therapies derived from its proprietary Inositune platform, which utilizes inositol phosphate analogs with adjustable properties. Inositec's lead product, INS-5010, is a non-antibiotic therapy designed to target colon infections caused by Clostridium difficile. Additionally, the company addresses soft tissue calcification disorders, focusing on vascular and renal calcification, including orphan indications. By selectively modifying the phosphate groups in inositol phosphate compounds, Inositec aims to create molecules with improved drug-like properties tailored for specific therapeutic applications.
Gamaya SA specializes in farmland analytics solutions aimed at enhancing the efficiency and sustainability of agricultural practices. Founded in 2015 and based in Lausanne, Switzerland, the company offers a range of tools tailored to specific crops, including SOYFIT for soybean cultivation, CANEFIT for sugarcane, and an Agronomic Intelligence Platform for large-scale tobacco growers. Gamaya's solutions enable early detection of diseases, pests, and weeds, as well as stress diagnostics and growth monitoring, which help optimize fertilization and predict yields. By leveraging advanced mapping and diagnostic technologies, Gamaya supports both large industrial farms and small-holder farmers in making informed decisions that improve production efficiency while minimizing environmental impact.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Equippo.com is a commercial equipment company that sells and buys used equipment for the construction industry. They bring together select manufacturers, dealers, leasing companies, and other trusted sellers of heavy equipment with buyers from all over the world, including markets like South America, Russia, and Poland. It operates an online marketplace for used construction equipment. They are very proud of their most important and unique technological innovation - the Equippo final price calculation engine makes it even easier to deal internationally: tariffs, transport, and logistics specific to your region are already included in the price displayed. Equippo.com was founded in 2014 and is headquartered in Zug, Switzerland, Equippo’s dedicated team is as international as its mission; buyers and sellers can speak with salespeople in more than nine languages.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease. CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensive insulin therapy but want flexibility and freedom from multiple daily injections. CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
L.E.S.S. designs and manufactures thinner, brighter, more uniform technical lighting systems. Thanks to our innovative approach, our aim is to deliver our customer with lighting systems that provide both intense and uniform light within a small form factor.
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Sonic Emotion AG, founded in 2002 and headquartered in Zurich, Switzerland, specializes in advanced audio solutions that create immersive sound experiences. The company's flagship technology, Sonic Emotion Absolute 3D, enables natural 3D sound reproduction using sound field control from as few as two channels, allowing for compact audio setups suitable for a variety of environments. Sonic Emotion AG caters to diverse markets, providing audio solutions for 3D cinemas, events, trade fairs, museums, theme parks, and dance shows. Additionally, the company offers audio simulation services, OEM licensing solutions, and a sound enhancement application named Headquake for Apple i-device products. With research facilities in France and sales offices across Asia, including China, Hong Kong, Taiwan, and Japan, Sonic Emotion AG is positioned to deliver cutting-edge audio technology globally.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
windeln.de, together with its subsidiaries, operates as an online retailer of products for babies, toddlers, children, and young mothers in Germany, Austria, Switzerland, the Czech Republic, Spain, and China. It operates through German Shop, International Shops, and Shopping Clubs segments. The company offers a range of products, including diapers, baby food, drugstore products, clothes, toys, strollers, child car seats, baby monitors, and children’s furniture.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
MerLion Pharmaceuticals GmbH a pharmaceutical company, develops antibacterial drugs and biological products. The company offers finafloxacin, a fluoroquinolone antibiotic for the treatment of infection. The company was founded in 2008 and is based in Berlin, Germany. As of August 21, 2006, MerLion Pharmaceuticals GmbH operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.
Nexthink is a global leader in digital experience management.
The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.
SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.
SilentSoft SA, founded in 2000 and headquartered in Morges, Switzerland, specializes in telemetry solutions that facilitate automated real-time communication between connected devices. The company offers a range of products, including StockView, a stock optimization solution for energy distributors, property managers, and end customers, and IndexView, designed for energy efficiency in properties. SilentSoft also provides monitoring devices for tanks and meters, enabling clients to receive real-time data and improve operational efficiency by reducing emergency deliveries and lowering carbon emissions. With additional offices in Meudon, France, and Willstätt, Germany, SilentSoft serves a diverse clientele across European countries, positioning itself as a key player in the Machine to Machine (M2M) industry.
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease. CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensive insulin therapy but want flexibility and freedom from multiple daily injections. CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Nexthink is a global leader in digital experience management.
The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Nexthink is a global leader in digital experience management.
The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.
Visonys
Venture Round in 2006
Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade's research expertise on intracellular peptides and signalling.
Covalys Biosciences
Series B in 2005
Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.
Avalon Photonics
Venture Round in 2003
Avalon Photonics produces world-class VCSELs (vertical cavity surface emitting lasers) for datacom, sensing, and measurement markets. These devices are enabling volume applications due to their exceptional performance, lower power consumption, and volume cost reduction.Avalon also produces unique, patent-protected, single-spatial-mode VCSELs with unsurpassed specifications required for many sensing and measurement applications. Avalon’s ISO 9001 production line achieves high quality, exceptional uniformity, and telecom-grade reliability devices. VCSELs can be provided from bare die up to fully packaged units with temperature control and fiber pigtailing.